Profile Technologies (PRTK) Misses Q2 EPS by 20c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Paratek Pharmaceuticals, Inc. Reports Second Quarter 2015 Financial and Operating Results
August 5, 2015 7:01 AM EDTCompleted a successful follow-on common stock offering to further strengthen company's financial position Initiated Phase 3 Registration Study of Omadacycline in Acute Bacterial Skin and Skin Structure Infections Strengthened Executive Team and Board of Directors with Key Additions
BOSTON, Aug. 5, 2015 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon tetracycline chemistry, today reported financial results for the quarter ended June 30, 2015. This quarter the company reported a net loss attributable to common stockholders of... More
